{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:56:46Z","timestamp":1792292206509,"version":"4.4.0"},"reference-count":178,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente"],"award-info":[{"award-number":["Ricerca Corrente"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Copper is an essential microelement that plays an important role in a wide variety of biological processes. Copper concentration has to be finely regulated, as any imbalance in its homeostasis can induce abnormalities. In particular, excess copper plays an important role in the etiopathogenesis of the genetic disease Wilson\u2019s syndrome, in neurological and neurodegenerative pathologies such as Alzheimer\u2019s and Parkinson\u2019s diseases, in idiopathic pulmonary fibrosis, in diabetes, and in several forms of cancer. Copper chelating agents are among the most promising tools to keep copper concentration at physiological levels. In this review, we focus on the most relevant compounds experimentally and clinically evaluated for their ability to counteract copper homeostasis deregulation. In particular, we provide a general overview of the main disorders characterized by a pathological increase in copper levels, summarizing the principal copper chelating therapies adopted in clinical trials.<\/jats:p>","DOI":"10.3390\/ijms21031069","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T03:13:27Z","timestamp":1581045207000},"page":"1069","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":194,"title":["Current Biomedical Use of Copper Chelation Therapy"],"prefix":"10.3390","volume":"21","author":[{"given":"Silvia","family":"Baldari","sequence":"first","affiliation":[{"name":"Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, via E. Chianesi 53, 00144 Rome, Italy"},{"name":"Department of Medical Surgical Sciences and Biotechnologies, University of Rome \u201cLa Sapienza\u201d, C.so della Repubblica 79, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Di Rocco","sequence":"additional","affiliation":[{"name":"Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, via E. Chianesi 53, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4182-2468","authenticated-orcid":false,"given":"Gabriele","family":"Toietta","sequence":"additional","affiliation":[{"name":"Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, via E. Chianesi 53, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1039\/C6MT00202A","article-title":"Defining the human copper proteome and analysis of its expression variation in cancers","volume":"9","author":"Blockhuys","year":"2017","journal-title":"Metallomics"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nchembio.72","article-title":"Mechanisms for copper acquisition, distribution and regulation","volume":"4","author":"Kim","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"797S","DOI":"10.1093\/ajcn\/63.5.797","article-title":"Copper biochemistry and molecular biology","volume":"63","author":"Linder","year":"1996","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jinorgbio.2018.10.009","article-title":"Chelating principles in Menkes and Wilson diseases: Choosing the right compounds in the right combinations at the right time","volume":"190","author":"Horn","year":"2019","journal-title":"J. Inorg. Biochem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.mam.2005.07.015","article-title":"Copper, oxidative stress, and human health","volume":"26","author":"Keen","year":"2005","journal-title":"Mol. Asp. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bpj.2015.11.025","article-title":"How mammalian cells acquire copper: An essential but potentially toxic metal","volume":"110","author":"Kaplan","year":"2016","journal-title":"Biophys. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1367-5931(03)00018-8","article-title":"Copper in medicine","volume":"7","author":"Brewer","year":"2003","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1474-4422(14)70190-5","article-title":"Wilson\u2019s disease and other neurological copper disorders","volume":"14","author":"Bandmann","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jtemb.2019.05.003","article-title":"Heavy metal toxicity: An update of chelating therapeutic strategies","volume":"54","author":"Kim","year":"2019","journal-title":"J. Trace Elem. Med. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jnutbio.2010.06.010","article-title":"The significance of copper chelators in clinical and experimental application","volume":"22","author":"Ding","year":"2011","journal-title":"J. Nutr. Biochem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/jn\/129.7.1251","article-title":"A delicate balance: Homeostatic control of copper uptake and distribution","volume":"129","author":"Lee","year":"1999","journal-title":"J. Nutr."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Weiss, K.H., Thurik, F., Gotthardt, D.N., Sch\u00e4fer, M., Teufel, U., Wiegand, F., Merle, U., Ferenci-Foerster, D., Maieron, A., and Stauber, R. (2013). Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin. Gastroenterol. Hepatol., 11.","DOI":"10.1016\/j.cgh.2013.03.012"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1158\/1535-7163.MCT-10-0523","article-title":"Triethylenetetramine pharmacology and its clinical applications","volume":"9","author":"Lu","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/med.20174","article-title":"Copper in diseases and treatments, and copper-based anticancer strategies","volume":"30","author":"Tisato","year":"2010","journal-title":"Med. Res. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.mehy.2018.08.003","article-title":"Copper as the most likely pathogenic divergence factor between lung fibrosis and emphysema","volume":"120","author":"Janssen","year":"2018","journal-title":"Med. Hypotheses"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/iub.1614","article-title":"Dissecting copper homeostasis in diabetes mellitus","volume":"69","author":"Lowe","year":"2017","journal-title":"Iubmb Life"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jtemb.2019.06.008","article-title":"Copper homeostasis as target of both consolidated and innovative strategies of anti-tumor therapy","volume":"55","author":"Barile","year":"2019","journal-title":"J. Trace Elem. Med. Biol."},{"key":"ref_18","first-page":"39","article-title":"Recognition, diagnosis, and management of Wilson\u2019s disease","volume":"223","author":"Brewer","year":"2000","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00018-007-7439-6","article-title":"Menkes disease","volume":"65","author":"Bertini","year":"2008","journal-title":"Cell Mol. Life Sci."},{"key":"ref_20","first-page":"71","article-title":"Skeletal dysplasia, occipital horns, diarrhea and obstructive uropathy- a new hereditary syndrome","volume":"11","author":"Lazoff","year":"1975","journal-title":"Birth Defects Orig. Artic. Ser."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/ng0193-7","article-title":"Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase","volume":"3","author":"Vulpe","year":"1993","journal-title":"Nat. Genet."},{"key":"ref_22","first-page":"570","article-title":"Similar splicing mutations of the Menkes\/mottled copper-transporting ATPase gene in occipital horn syndrome and the blotchy mouse","volume":"56","author":"Das","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2018.12.005","article-title":"A systematic review and evidence-based guideline for diagnosis and treatment of Menkes disease","volume":"126","author":"Vairo","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/ng1293-327","article-title":"The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene","volume":"5","author":"Bull","year":"1993","journal-title":"Nat. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/jhep.2003.50252","article-title":"A practice guideline on Wilson disease","volume":"37","author":"Roberts","year":"2003","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1002\/hep.22261","article-title":"Diagnosis and treatment of Wilson disease: An update","volume":"47","author":"Roberts","year":"2008","journal-title":"Hepatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.21037\/atm.2019.02.48","article-title":"Current anti-copper therapies in management of Wilson disease","volume":"7","author":"Mohr","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0002-9343(56)90066-3","article-title":"Penicillamine, a new oral therapy for Wilson\u2019s disease","volume":"21","author":"Walshe","year":"1956","journal-title":"Am. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneur.1987.00520170020016","article-title":"Worsening of neurologic syndrome in patients with Wilson\u2019s disease with initial penicillamine therapy","volume":"44","author":"Brewer","year":"1987","journal-title":"Arch. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-199205000-00004","article-title":"Wilson disease","volume":"71","author":"Brewer","year":"1992","journal-title":"Med. (Baltim.)"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0022-510X(87)90116-X","article-title":"Management of Wilson\u2019s disease with zinc sulphate. Experience in a series of 27 patients","volume":"77","author":"Hoogenraad","year":"1987","journal-title":"J. Neurol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0140-6736(82)92201-2","article-title":"Treatment of Wilson\u2019s disease with trientine (triethylene tetramine) dihydrochloride","volume":"1","author":"Walshe","year":"1982","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/jn\/111.8.1353","article-title":"Regulation of intestinal metallothionein biosynthesis in rats by dietary zinc","volume":"111","author":"Menard","year":"1981","journal-title":"J. Nutr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0022-2143(98)90039-7","article-title":"Treatment of Wilson\u2019s disease with zinc: XV long-term follow-up studies","volume":"132","author":"Brewer","year":"1998","journal-title":"J. Lab. Clin Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2174\/1570159X14666151130222427","article-title":"Current drug managements of Wilson\u2019s disease: From West to East","volume":"14","author":"Li","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3748\/wjg.v4.i6.530","article-title":"Comparison of long lasting therapeutic effects between succimer and penicillamine on hepatolenticular degeneration","volume":"4","author":"Ren","year":"1998","journal-title":"World J. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archneur.1991.00530130050019","article-title":"Initial therapy of patients with Wilson\u2019s disease with tetrathiomolybdate","volume":"48","author":"Brewer","year":"1991","journal-title":"Arch. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archneur.1994.00540180023009","article-title":"Treatment of Wilson\u2019s disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients","volume":"51","author":"Brewer","year":"1994","journal-title":"Arch. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/archneur.1996.00550100103019","article-title":"Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy","volume":"53","author":"Brewer","year":"1996","journal-title":"Arch. Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/archneur.63.4.521","article-title":"Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease","volume":"63","author":"Brewer","year":"2006","journal-title":"Arch. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S2468-1253(17)30293-5","article-title":"Bis-choline tetrathiomolybdate in patients with Wilson\u2019s disease: An open-label, multicentre, phase 2 study","volume":"2","author":"Weiss","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/13543784.2018.1482274","article-title":"WTX101\u2013An investigational drug for the treatment of Wilson disease","volume":"27","author":"Weiss","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1101\/gad.314658.118","article-title":"DPM-1001 decreased copper levels and ameliorated deficits in a mouse model of Wilson\u2019s disease","volume":"32","author":"Krishnan","year":"2018","journal-title":"Genes Dev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1172\/JCI85226","article-title":"Methanobactin reverses acute liver failure in a rat model of Wilson disease","volume":"126","author":"Lichtmannegger","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijpharm.2016.08.040","article-title":"Delivery of Copper-chelating Trientine (TETA) to the central nervous system by surface modified liposomes","volume":"512","author":"Tremmel","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Farzaei, M.H., Zobeiri, M., Parvizi, F., El-Senduny, F.F., Marmouzi, I., Coy-Barrera, E., Naseri, R., Nabavi, S.M., Rahimi, R., and Abdollahi, M. (2018). Curcumin in liver diseases: A systematic review of the cellular mechanisms of oxidative stress and clinical perspective. Nutrients, 10.","DOI":"10.3390\/nu10070855"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.21037\/atm.2019.03.18","article-title":"Clinical management of Wilson disease","volume":"7","author":"Hedera","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.21037\/atm.2018.12.09","article-title":"Wilson disease-treatment perspectives","volume":"7","author":"Litwin","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11940-000-0023-0","article-title":"Alzheimer\u2019s Disease","volume":"2","author":"Schachter","year":"2000","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer\u2019s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_51","first-page":"309","article-title":"Role of free radicals and metal ions in the pathogenesis of Alzheimer\u2019s disease","volume":"36","author":"Atwood","year":"1999","journal-title":"Met. Ions Biol. Syst."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.tips.2018.10.001","article-title":"Copper and zinc dysregulation in Alzheimer\u2019s disease","volume":"39","author":"Sensi","year":"2018","journal-title":"Trends Pharm. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ccr.2019.06.018","article-title":"Copper imbalance in Alzheimer\u2019s disease: Convergence of the chemistry and the clinic","volume":"397","author":"Kepp","year":"2019","journal-title":"Coord. Chem. Rev."},{"key":"ref_54","first-page":"231","article-title":"Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer\u2019s disease","volume":"3","author":"Basun","year":"1991","journal-title":"J. Neural. Transm. Park Dis. Dement. Sect."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Bagheri, S., Squitti, R., Haertl\u00e9, T., Siotto, M., and Saboury, A.A. (2017). Role of copper in the onset of Alzheimer\u2019s disease compared to other metals. Front. Aging Neurosci., 9.","DOI":"10.3389\/fnagi.2017.00446"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1039\/C6MT00101G","article-title":"Non-ceruloplasmin bound copper and ATP7B gene variants in Alzheimer\u2019s disease","volume":"8","author":"Squitti","year":"2016","journal-title":"Metallomics"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2011.10.446","article-title":"Elevated labile Cu is associated with oxidative pathology in Alzheimer disease","volume":"52","author":"James","year":"2012","journal-title":"Free Radic Biol. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0896-6273(01)00317-8","article-title":"Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer\u2019s disease transgenic mice","volume":"30","author":"Cherny","year":"2001","journal-title":"Neuron"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.exger.2004.08.016","article-title":"Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer\u2019s amyloidogenesis","volume":"39","author":"Dedeoglu","year":"2004","journal-title":"Exp. Gerontol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1365-2362.2002.00933.x","article-title":"D-penicillamine reduces serum oxidative stress in Alzheimer\u2019s disease patients","volume":"32","author":"Squitti","year":"2002","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1474-4422(08)70167-4","article-title":"Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer\u2019s disease: A phase IIa, double-blind, randomised, placebo-controlled trial","volume":"7","author":"Lannfelt","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Sampson, E.L., Jenagaratnam, L., and McShane, R. (2014). Metal protein attenuating compounds for the treatment of Alzheimer\u2019s dementia. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD005380.pub5"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Drew, S.C. (2017). The case for abandoning therapeutic chelation of copper ions in Alzheimer\u2019s disease. Front. Neurosci., 11.","DOI":"10.3389\/fnins.2017.00317"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Squitti, R., Salustri, C., Rongioletti, M., and Siotto, M. (2017). Commentary: The case for abandoning therapeutic chelation of copper ions in Alzheimer\u2019s disease. Front. Neurol., 8.","DOI":"10.3389\/fneur.2017.00503"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1021\/ic4031377","article-title":"Site-specific copper-catalyzed oxidation of \u03b1-synuclein: Tightening the link between metal binding and protein oxidative damage in Parkinson\u2019s disease","volume":"53","author":"Miotto","year":"2014","journal-title":"Inorg. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fnins.2017.00114","article-title":"Metallothionein, Copper and Alpha-Synuclein in Alpha-Synucleinopathies","volume":"11","author":"Okita","year":"2017","journal-title":"Front. Neurosci."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Ajsuvakova, O.P., Tinkov, A.A., Willkommen, D., Skalnaya, A.A., Danilov, A.B., Pilipovich, A.A., Aschner, M., Skalny, A.V., Michalke, B., and Skalnaya, M.G. (2019). Assessment of copper, iron, zinc and manganese status and speciation in patients with Parkinson\u2019s disease: A pilot study. J. Trace Elem. Med. Biol.","DOI":"10.1016\/j.jtemb.2019.126423"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.2174\/0929867325666171129124616","article-title":"Metals and Parkinson\u2019s disease: Mechanisms and biochemical processes","volume":"25","author":"Bjorklund","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Montes, S., Rivera-Mancia, S., Diaz-Ruiz, A., Tristan-Lopez, L., and Rios, C. (2014). Copper and copper proteins in Parkinson\u2019s disease. Oxid. Med. Cell Longev., 2014.","DOI":"10.1155\/2014\/147251"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Tosato, M., and Di Marco, V. (2019). Metal chelation therapy and Parkinson\u2019s disease: A critical review on the thermodynamics of complex formation between relevant metal ions and promising or established drugs. Biomolecules, 9.","DOI":"10.3390\/biom9070269"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/ars.2013.5593","article-title":"Targeting chelatable iron as a therapeutic modality in Parkinson\u2019s disease","volume":"21","author":"Devos","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11064-014-1508-7","article-title":"Characterization of the neuroprotective potential of derivatives of the iron chelating drug deferiprone","volume":"40","author":"Maher","year":"2015","journal-title":"Neurochem. Res."},{"key":"ref_73","first-page":"998","article-title":"Molecular factors affecting the complex formation between deferiprone (L1) and Cu(II). Possible implications on efficacy and toxicity","volume":"51","author":"Pashalidis","year":"2001","journal-title":"Arzneimittelforschung"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00775-019-01650-9","article-title":"Effective inhibition of copper-catalyzed production of hydroxyl radicals by deferiprone","volume":"24","author":"Timoshnikov","year":"2019","journal-title":"J. Biol. Inorg. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Nu\u00f1ez, M.T., and Chana-Cuevas, P. (2018). New perspectives in iron chelation therapy for the treatment of neurodegenerative diseases. Pharmaceuticals (Basel), 11.","DOI":"10.3390\/ph11040109"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pharmthera.2016.09.010","article-title":"Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?","volume":"169","author":"Clarke","year":"2017","journal-title":"Pharm. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/jcb.10413","article-title":"Lysyl oxidase: Properties, specificity, and biological roles inside and outside of the cell","volume":"88","author":"Kagan","year":"2003","journal-title":"J. Cell Biochem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm.2208","article-title":"Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment","volume":"16","author":"Spangler","year":"2010","journal-title":"Nat. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1080\/1061186X.2018.1550649","article-title":"LOX\/LOXL in pulmonary fibrosis: Potential therapeutic targets","volume":"27","author":"Chen","year":"2019","journal-title":"J. Drug Target."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1067\/mlc.2003.20","article-title":"Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice","volume":"141","author":"Brewer","year":"2003","journal-title":"J. Lab. Clin. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s12011-014-0142-1","article-title":"The copper chelator tetrathiomolybdate regressed bleomycin-induced pulmonary fibrosis in mice, by reducing lysyl oxidase expressions","volume":"162","author":"Ovet","year":"2014","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.2337\/dc14-S081","article-title":"Diagnosis and classification of diabetes mellitus","volume":"37","author":"Association","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12011-016-0877-y","article-title":"Copper in diabetes mellitus: A meta-analysis and systematic review of plasma and serum studies","volume":"177","author":"Qiu","year":"2017","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1016\/j.clnu.2018.12.032","article-title":"Association between plasma concentration of copper and gestational diabetes mellitus","volume":"38","author":"Li","year":"2019","journal-title":"Clin. Nutr."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/er.2001-0039","article-title":"Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of type 2 diabetes","volume":"23","author":"Evans","year":"2002","journal-title":"Endocr. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/03630260701727077","article-title":"The role of zinc, copper and iron in the pathogenesis of diabetes and diabetic complications: Therapeutic effects by chelators","volume":"32","author":"Zheng","year":"2008","journal-title":"Hemoglobin"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.2337\/diabetes.53.9.2501","article-title":"Regeneration of the heart in diabetes by selective copper chelation","volume":"53","author":"Cooper","year":"2004","journal-title":"Diabetes"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1021\/bi401444n","article-title":"Biomolecular mode of action of metformin in relation to its copper binding properties","volume":"53","author":"Erhardt","year":"2014","journal-title":"Biochemistry"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41574-019-0242-2","article-title":"Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus","volume":"15","author":"Foretz","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1507\/endocrj.K09E-051","article-title":"Role of copper ion in the pathogenesis of type 2 diabetes","volume":"56","author":"Tanaka","year":"2009","journal-title":"Endocr. J."},{"key":"ref_92","first-page":"4353","article-title":"Cancer risk in relation to serum copper levels","volume":"49","author":"Coates","year":"1989","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/1097-0142(19830901)52:5<868::AID-CNCR2820520521>3.0.CO;2-K","article-title":"Copper and zinc levels in normal and malignant tissues","volume":"52","author":"Margalioth","year":"1983","journal-title":"Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3109\/00016486609127083","article-title":"Biochemical studies on copper, copper oxidase, magnesium, sulfur, calcium and phosphorus in cancer of the larynx","volume":"61","author":"Paiva","year":"1966","journal-title":"Acta Otolaryngol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/1097-0142(19800415)45:8<2156::AID-CNCR2820450824>3.0.CO;2-C","article-title":"Serum copper levels in non-Hodgkin\u2019s lymphoma","volume":"45","author":"Khilanani","year":"1980","journal-title":"Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Khadem-Ansari, M.H., Asoudeh, M., Gheshlaghi, H.F.K., Nozari, S., Zarringol, M., Maroufi, N.F., and Faridvand, Y. (2018). Copper and zinc in stage I multiple myeloma: Relation with ceruloplasmin, lipid peroxidation, and superoxide dismutase activity. Horm. Mol. Biol. Clin. Investig., 37.","DOI":"10.1515\/hmbci-2018-0055"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ejim.2012.07.009","article-title":"Copper levels in patients with hematological malignancies","volume":"23","author":"Kaiafa","year":"2012","journal-title":"Eur. J. Intern. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1002\/ijc.31991","article-title":"Serum copper and zinc levels at diagnosis and hepatocellular carcinoma survival in the Guangdong Liver Cancer Cohort","volume":"144","author":"Fang","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1385\/BTER:82:1-3:001","article-title":"Analysis of serum copper and zinc concentrations in cancer patients","volume":"82","author":"Zowczak","year":"2001","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jso.2930520311","article-title":"Serum and tissue trace elements in colorectal cancer","volume":"52","author":"Gupta","year":"1993","journal-title":"J. Surg. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1177\/0300060518798507","article-title":"Association between serum copper levels and lung cancer risk: A meta-analysis","volume":"46","author":"Zhang","year":"2018","journal-title":"J. Int. Med. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01731643","article-title":"Serum ceruloplasmin and copper levels in patients with primary brain tumors","volume":"62","author":"Kalina","year":"1984","journal-title":"Klin. Wochenschr."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/01635589209514187","article-title":"Evidence for increased non-ceruloplasmin copper in early-stage human breast cancer serum","volume":"17","author":"Dabek","year":"1992","journal-title":"Nutr. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/2211-5463.12060","article-title":"Transcriptome analysis of copper homeostasis genes reveals coordinated upregulation of SLC31A1,SCO1, and COX11 in colorectal cancer","volume":"6","author":"Barresi","year":"2016","journal-title":"FEBS Open Bio."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/sj.onc.1209265","article-title":"Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: Comprehensive profiles by representational difference analysis, microarrays and proteomics","volume":"25","author":"Nagaraja","year":"2006","journal-title":"Oncogene"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1677\/erc.0.0110255","article-title":"Copper deficiency as an anti-cancer strategy","volume":"11","author":"Goodman","year":"2004","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Lopez, J., Ramchandani, D., and Vahdat, L. (2019). Copper depletion as a therapeutic strategy in cancer. Met. Ions Life Sci., 19.","DOI":"10.1515\/9783110527872-012"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1126\/science.349.6244.129","article-title":"Cancer\u2019s copper connections","volume":"349","author":"Garber","year":"2015","journal-title":"Science"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Petruzzelli, R., and Polishchuk, R.S. (2019). Activity and Trafficking of Copper-Transporting ATPases in Tumor Development and Defense against Platinum-Based Drugs. Cells, 8.","DOI":"10.3390\/cells8091080"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1039\/C5MT00149H","article-title":"Targeting copper in cancer therapy: \u2018Copper That Cancer\u2019","volume":"7","author":"Denoyer","year":"2015","journal-title":"Metallomics"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ctrv.2008.07.004","article-title":"Elevated copper and oxidative stress in cancer cells as a target for cancer treatment","volume":"35","author":"Gupte","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/(SICI)1097-4644(19980601)69:3<326::AID-JCB10>3.0.CO;2-A","article-title":"Copper stimulates proliferation of human endothelial cells under culture","volume":"69","author":"Hu","year":"1998","journal-title":"J. Cell Biochem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/annonc\/mds654","article-title":"Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse","volume":"24","author":"Jain","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1006\/bbrc.1997.7018","article-title":"Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells","volume":"236","author":"Soncin","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1039\/C8MT00280K","article-title":"Copper affects the binding of HIF-1\u03b1 to the critical motifs of its target genes","volume":"11","author":"Wu","year":"2019","journal-title":"Metallomics"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1128\/MCB.05722-11","article-title":"A novel role for copper in Ras\/mitogen-activated protein kinase signaling","volume":"32","author":"Turski","year":"2012","journal-title":"Mol. Cell Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"9157","DOI":"10.1074\/jbc.M709463200","article-title":"Novel role of antioxidant-1 (Atox1) as a copper-dependent transcription factor involved in cell proliferation","volume":"283","author":"Itoh","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nchem.2381","article-title":"Inhibition of human copper trafficking by a small molecule significantly attenuates cancer cell proliferation","volume":"7","author":"Wang","year":"2015","journal-title":"Nat. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"19507","DOI":"10.1073\/pnas.1318431110","article-title":"Bioavailable copper modulates oxidative phosphorylation and growth of tumors","volume":"110","author":"Ishida","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nature13180","article-title":"Copper is required for oncogenic BRAF signalling and tumorigenesis","volume":"509","author":"Brady","year":"2014","journal-title":"Nature"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2217\/mmt-2015-0005","article-title":"Copper suppression as cancer therapy: The rationale for copper chelating agents in BRAF V600 mutated melanoma","volume":"3","author":"Sammons","year":"2016","journal-title":"Melanoma Manag."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Baldari, S., Di Rocco, G., Heffern, M.C., Su, T.A., Chang, C.J., and Toietta, G. (2019). Effects of copper chelation on BRAF(V600E) positive colon carcinoma cells. Cancers, 11.","DOI":"10.3390\/cancers11050659"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1158\/1078-0432.CCR-17-3705","article-title":"Copper chelation as targeted therapy in a mouse model of oncogenic BRAF-driven papillary thyroid cancer","volume":"24","author":"Xu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Choi, R., Kim, M.J., Sohn, I., Kim, S., Kim, I., Ryu, J.M., Choi, H.J., Kim, J.M., Lee, S.K., and Yu, J. (2018). Serum trace elements and their associations with breast cancer subgroups in Korean breast cancer patients. Nutrients, 11.","DOI":"10.3390\/nu11010037"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Wang, T.H., Hsia, S.M., and Shieh, T.M. (2016). Lysyl oxidase and the tumor microenvironment. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18010062"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"MacDonald, G., Nalvarte, I., Smirnova, T., Vecchi, M., Aceto, N., Dolemeyer, A., Frei, A., Lienhard, S., Wyckoff, J., and Hess, D. (2014). Memo is a copper-dependent redox protein with an essential role in migration and metastasis. Sci. Signal., 7.","DOI":"10.1126\/scisignal.2004870"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Li, S., Zhang, J., Yang, H., Wu, C., Dang, X., and Liu, Y. (2015). Copper depletion inhibits CoCl2-induced aggressive phenotype of MCF-7 cells via downregulation of HIF-1 and inhibition of Snail\/Twist-mediated epithelial-mesenchymal transition. Sci. Rep., 5.","DOI":"10.1038\/srep12410"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Blockhuys, S., and Wittung-Stafshede, P. (2017). Roles of copper-binding proteins in breast cancer. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18040871"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Morrissey, M.A., Jayadev, R., Miley, G.R., Blebea, C.A., Chi, Q., Ihara, S., and Sherwood, D.R. (2016). SPARC promotes cell invasion in vivo by decreasing type IV collagen levels in the basement membrane. Plos Genet., 12.","DOI":"10.1101\/037218"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10637-008-9165-9","article-title":"A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer","volume":"27","author":"Gartner","year":"2009","journal-title":"Investig. New Drugs"},{"key":"ref_131","first-page":"1","article-title":"Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study","volume":"6","author":"Brewer","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10534-008-9174-3","article-title":"The role of copper in drug-resistant murine and human tumors","volume":"22","author":"Majumder","year":"2009","journal-title":"Biometals"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/iub.1722","article-title":"Copper efflux transporters ATP7A and ATP7B: Novel biomarkers for platinum drug resistance and targets for therapy","volume":"70","author":"Li","year":"2018","journal-title":"Iubmb Life"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"106","DOI":"10.5306\/wjco.v7.i1.106","article-title":"Role of copper transporters in platinum resistance","volume":"7","author":"Kilari","year":"2016","journal-title":"World J. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1158\/0008-5472.CAN-12-0888","article-title":"Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy","volume":"72","author":"Kuo","year":"2012","journal-title":"Cancer Res."},{"key":"ref_136","first-page":"4157","article-title":"Overcoming platinum drug resistance with copper-lowering agents","volume":"33","author":"Chen","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1535-7163.MCT-11-0864","article-title":"Overcoming platinum resistance through the use of a copper-lowering agent","volume":"11","author":"Fu","year":"2012","journal-title":"Mol. Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10637-013-0051-8","article-title":"Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies","volume":"32","author":"Fu","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fonc.2019.00437","article-title":"A dose escalation study of trientine plus carboplatin and pegylated liposomal doxorubicin in women with a first relapse of epithelial ovarian, tubal, and peritoneal cancer within 12 months after platinum-based chemotherapy","volume":"9","author":"Huang","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Spengler, G., Gajd\u00e1cs, M., Mar\u0107, M.A., Dom\u00ednguez-\u00c1lvarez, E., and Sanmart\u00edn, C. (2019). Organoselenium compounds as novel adjuvants of chemotherapy drugs-A promising approach to fight cancer drug resistance. Molecules, 24.","DOI":"10.3390\/molecules24020336"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1080\/10408398.2018.1548427","article-title":"Does dietary intake of selenium protect against cancer? A systematic review and meta-analysis of population-based prospective studies","volume":"60","author":"Kuria","year":"2020","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"10758","DOI":"10.1039\/C7DT01955F","article-title":"A Perspective - can copper complexes be developed as a novel class of therapeutics?","volume":"46","author":"Wehbe","year":"2017","journal-title":"Dalton Trans."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Denoyer, D., Clatworthy, S.A.S., and Cater, M.A. (2018). Copper complexes in cancer therapy. Met. Ions Life Sci., 18.","DOI":"10.1515\/9783110470734-016"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.3109\/10428194.2016.1138293","article-title":"A phase I study of elesclomol sodium in patients with acute myeloid leukemia","volume":"57","author":"Hedley","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.1093\/nar\/gkv467","article-title":"Intercalation processes of copper complexes in DNA","volume":"43","author":"Cheatham","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_146","first-page":"1957","article-title":"Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction","volume":"9","author":"Wachsberger","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/archotol.132.3.333","article-title":"Combination tetrathiomolybdate and radiation therapy in a mouse model of head and neck squamous cell carcinoma","volume":"132","author":"Khan","year":"2006","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_148","first-page":"989","article-title":"Ammonium tetrathiomolybdate enhances the antitumor effects of cetuximab via the suppression of osteoclastogenesis in head and neck squamous carcinoma","volume":"52","author":"Morisawa","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.biomaterials.2019.01.007","article-title":"Multifunctional nanoparticles based on a polymeric copper chelator for combination treatment of metastatic breast cancer","volume":"195","author":"Zhou","year":"2019","journal-title":"Biomaterials"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Voli, F., Lerra, L., Kimpton, K., Saletta, F., Shen, S., Cirillo, G., Kavallaris, M., and Vittorio, O. (2019). Copper homeostasis: A new player in anti-tumor immune response. Cancer Res., 79.","DOI":"10.1158\/1538-7445.SABCS18-3224"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1158\/1078-0432.CCR-12-0697","article-title":"Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV","volume":"18","author":"Yoo","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Yoo, J.Y., Yu, J.G., Kaka, A., Pan, Q., Kumar, P., Kumar, B., Zhang, J., Mazar, A., Teknos, T.N., and Kaur, B. (2015). ATN-224 enhances antitumor efficacy of oncolytic herpes virus against both local and metastatic head and neck squamous cell carcinoma. Mol. Oncolytics, 2.","DOI":"10.1038\/mto.2015.8"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/2159-8290.CD-19-0292","article-title":"Targeting autophagy in cancer: Recent advances and future directions","volume":"9","author":"Amaravadi","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1053\/j.gastro.2018.11.032","article-title":"Activation of autophagy, observed in liver tissues from patients with Wilson disease and from ATP7B-deficient animals, protects hepatocytes from copper-induced apoptosis","volume":"156","author":"Polishchuk","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Tsang, T., Posimo, J.M., Gudiel, A.A., Cicchini, M., Feldser, D.M., and Brady, D.C. (2019). Copper is an essential regulator of the autophagic kinases ULK1\/2 to drive lung adenocarcinoma. bioRxiv, 816587.","DOI":"10.1101\/816587"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e12568","DOI":"10.1111\/cpr.12568","article-title":"Blockage of SLC31A1-dependent copper absorption increases pancreatic cancer cell autophagy to resist cell death","volume":"52","author":"Yu","year":"2019","journal-title":"Cell Prolif."},{"key":"ref_157","first-page":"4854","article-title":"Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis","volume":"62","author":"Pan","year":"2002","journal-title":"Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.1158\/0008-5472.CAN-16-1190","article-title":"Copper chelation inhibits BRAF V600E-driven melanomagenesis and counters resistance to BRAF V600E and MEK1\/2 inhibitors","volume":"77","author":"Brady","year":"2017","journal-title":"Cancer Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/archotol.129.7.781","article-title":"Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model","volume":"129","author":"Cox","year":"2003","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/archotol.131.3.204","article-title":"The effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth in squamous cell carcinoma of the head and neck","volume":"131","author":"Teknos","year":"2005","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1158\/1535-7163.MCT-06-0524","article-title":"Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer","volume":"6","author":"Hassouneh","year":"2007","journal-title":"Mol. Cancer"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1158\/1078-0432.CCR-06-0171","article-title":"Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1","volume":"12","author":"Juarez","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/sj.neo.7900218","article-title":"Radiotherapy and antiangiogenic TM in lung cancer","volume":"4","author":"Khan","year":"2002","journal-title":"Neoplasia"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Liu, H., Zhang, X., Fan, T., Li, Y., Zhang, K., Ma, S., Song, Y., Xu, J., Wang, X., and Wang, F. (2018). Enhanced efficacy of combined TM with cisplatin targeting esophageal squamous cell carcinoma via suppressing Stat3 signaling pathway. 13, 808\u2013815.","DOI":"10.2139\/ssrn.3215552"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Kim, K.K., Han, A., Yano, N., Ribeiro, J.R., Lokich, E., Singh, R.K., and Moore, R.G. (2015). Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers. Sci. Rep., 5.","DOI":"10.1038\/srep15911"},{"key":"ref_166","first-page":"890","article-title":"Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: Modulation by tetrathiomolybdate, KRAS\/BRAF mutations and c-MYC\/p53 status","volume":"13","author":"Cornejo","year":"2019","journal-title":"Ecancermedicalscience"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/ijc.1537","article-title":"The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells","volume":"94","author":"Yoshii","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_168","first-page":"1121","article-title":"Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor","volume":"137","author":"Brem","year":"1990","journal-title":"Am. J. Pathol."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Crowe, A., Jackaman, C., Beddoes, K.M., Ricciardo, B., and Nelson, D.J. (2013). Rapid copper acquisition by developing murine mesothelioma: Decreasing bioavailable copper slows tumor growth, normalizes vessels and promotes T cell infiltration. Plos ONE, 8.","DOI":"10.1371\/journal.pone.0073684"},{"key":"ref_170","first-page":"1666","article-title":"Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer","volume":"9","author":"Redman","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Sahota, S., Willis, A., Kornhauser, N., Ward, M., Cobham, M., Cigler, T., Moore, A., Andreopoulou, E., Fitzpatrick, V., and Schneider, S. (2018). A phase II study of copper-depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence: Updated results. Cancer Res., 78.","DOI":"10.1158\/1538-7445.SABCS17-P1-10-02"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1158\/1078-0432.CCR-16-1326","article-title":"Influencing the tumor microenvironment: A phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases","volume":"23","author":"Chan","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000106066","article-title":"Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer","volume":"71","author":"Henry","year":"2006","journal-title":"Oncology"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.athoracsur.2008.03.016","article-title":"A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: Final results","volume":"86","author":"Pass","year":"2008","journal-title":"Ann. Thorac. Surg."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10637-012-9864-0","article-title":"Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer","volume":"31","author":"Schneider","year":"2013","journal-title":"Investig. New Drugs"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1215\/S1152851704000869","article-title":"Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma","volume":"7","author":"Brem","year":"2005","journal-title":"Neuro. Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"7526","DOI":"10.1158\/1078-0432.CCR-08-0315","article-title":"Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors","volume":"14","author":"Lowndes","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.urolonc.2011.04.009","article-title":"A non-comparative randomized phase II study of 2 doses of ATN-224, a copper\/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-na\u00efve prostate cancer","volume":"31","author":"Lin","year":"2013","journal-title":"Urol. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/3\/1069\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:55:09Z","timestamp":1760172909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/3\/1069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,6]]},"references-count":178,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["ijms21031069"],"URL":"https:\/\/doi.org\/10.3390\/ijms21031069","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,6]]}}}